Reperfusion of the ischemic myocardium results in the loss of endothelium-dependent relaxation. We have shown recently that the alternate complement pathway is activated immediately on reperfusion of the ischemic porcine myocardium. We hypothesized that complement activation directly attenuates endothelium-dependent relaxation of porcine coronary arteries. Bradykinin (BK) or substance P concentrationdependently relaxed precontracted (U46619, 50 nmol/L) left anterior descending coronary artery (LAD) rings in vitro. Addition of zymosan to human (10%) or porcine (10%) serum for 30 minutes significantly (P less than 0.05) increased the EC 50 of BK-induced LAD relaxation from 4 plus minus 1 to 418 plus minus 159 nmol/L (n equals 8) and from 9 plus minus 3 to 281 plus minus 132 nmol/L (n equals 7), respectively. Similarly, addition of zymosan to 10% human serum (HS) for 30 minutes increased the EC 50 of substance P-induced LAD relaxation from 0.4 plus minus 0.1 to 30 plus minus 14 nmol/L (n equals 9, P less than .05).
demonstrate that monoclonal antibodies against neutrophil or endothelial cell adherence proteins provide not only myocardial protection but also preserve endothelium-dependent relaxation. [9] [10] [11] [12] A significant amount of evidence suggests that the complement cascade plays an important role in myocardial ischemia and reperfusion injury. First, the alternate complement pathway is activated immediately on reperfusion of the ischemic porcine myocardium. [13] Second, subcellular membrane fragments released after myocardial ischemia have been shown to activate the complement cascade. [14, 15] Third, depletion of complement with cobra venom factor or inhibition of complement activation with soluble complement receptor type 1 (sCR1) provides protection against experimental models of myocardial ischemia and reperfusion injury. [16, 17] Fourth, C5b-9 directly induces cardiac dysfunction in the isolated human plasma-perfused rabbit heart. [18, 19] Fifth, intracoronary infusion of porcine C5a induces myocardial ischemia. [20, 21] Sixth, recent evidence from our laboratory demonstrates that a monoclonal antibody against porcine C5a protects the ischemic porcine myocardium against reperfusion injury. [13] Thus, the complement system plays an important role in myocardial ischemia and reperfusion injury. However, the mechanisms of complement-induced myocardial injury and the importance of the various complement components have not been established fully.
There is evidence to suggest that complement may attenuate endothelial cell function. The terminal membrane attack complex (MAC, C5b-9) is observed along endothelial cells soon after reperfusion and may elicit endothelial cell injury by forming transmembrane channels. [16, 22] Additionally, complement activation releases heparan sulfate from cultured porcine endothelial cells. [23, 24] Heparan sulfate tethers superoxide dismutase to endothelial cells and attaches the endothelium to the extracellular matrix. [23] Further, complement activation and C5b-9 formation have been shown to upregulate the PMN adherence protein, P-selectin, on endothelial cells. [25, 26] However, the direct role of the complement system on endothelial cell dysfunction and the loss of endothelium-dependent relaxation is unknown.
Recently, we have observed that the alternate complement cascade is activated immediately on reperfusion of the ischemic porcine myocardium. [13] This time course of complement activation parallels the maximal loss of endothelium-dependent relaxation observed in another model of myocardial ischemia and reperfusion. [3] In the present study, we investigated the potential direct effects of complement activation on endothelium-dependent relaxation of the porcine coronary vasculature. We hypothesized that complement activation would directly attenuate endothelium-dependent relaxation of porcine coronary arterial rings in vitro in the absence of bloodborne inflammatory cells (ie, PMNs). Our data demonstrate that complement activation directly attenuates endotheliumdependent relaxation of porcine coronary vessels. The presence of C5b-9 on the vascular endothelium, normal endothelium-dependent relaxation of left anterior descending coronary artery (LAD) rings after activation of C8-depleted serum, and abnormal endothelium-dependent relaxation of LAD rings after activation of C8-supplemented C8-depleted serum suggest that the loss of endothelium-dependent relaxation is mediated by the formation of C5b-9.
Materials and Methods

Animal and Human Research Guidelines
All procedures in the present study were approved by the Human Subjects Review Committee and the Animal Use and Care Administrative Advisory Committee of the University of California, Davis, and the Harvard Medical Area Standing Committee on Animals.
Materials
Bradykinin, substance P, N omega -nitro-L-arginine methyl ester (L-NAME), and zymosan were purchased from Sigma Chemical Co. U46619 was a gift from Upjohn. Complement compounds, including C8 and C8-depleted human serum, were purchased from Quidel. sCR1 was a gift from SmithKline and Beecham. Mouse anti-human C5b-9 antibodies were purchased from Dako and Quidel.
Coronary Vessel Preparation
Domestic swine (35 to 45 kg) were premedicated and anesthetized as described previously. [21] The hearts were removed, 2 to 3 cm of the proximal portion of the LAD was dissected free, and connective tissue was removed. The vessels were cut into 2-to 3-mm rings and mounted between a pair of stainless steel hooks. One hook was attached to a force transducer (Grass model FT03). The other hook was attached to the bottom of a warmed (37 degrees C) organ bath (5 mL). The organ bath was filled and oxygenated (95% O 2 /5% CO 2 ) with Krebs-Henseleit (KH) buffer as we have described previously. [27, 28] Preliminary length-tension studies in our laboratory demonstrated that a preload of 4 to 6 g was optimal for contraction and relaxation studies with this size porcine coronary artery. The KH buffer was replaced every 20 to 30 minutes. The analog signals were digitized, analyzed, and stored by a commercially available software system (PO-NEMAH) on a 486-based computer.
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After an equilibration period of 1 hour, the rings were contracted with 100 mmol/L K plus KH buffer and washed.
This procedure was repeated three times. If necessary, the preload was adjusted back to 4 to 6 g after each 100
mmol/L K plus KH buffer-induced contraction. The LAD rings then were contracted with U46619 (50 nmol/L), which resulted in a stable contraction for 15 to 20 minutes. Use of other vasoconstricting agents (ie, norepinephrine, phenylephrine, prostaglandin F sub 2 alpha, and acetylcholine) in preliminary studies resulted in poor or unstable contractions. At the peak of contraction, a doseresponse curve to bradykinin (BK, 10 minus 9 to 10 minus 6 mol/L) or substance P (10 minus 10 to 10 minus 8 mol/L) was performed by adding cumulative amounts of these endotheliumdependent relaxing agents. [29] [30] [31] The LAD rings then were washed with KH buffer and allowed to return to baseline.
After 1 hour, each of the rings was then bathed in one of the following supplemented KH buffers: (1) 10% porcine serum, (2) 10% human serum, (3) zymosan (1 mg/mL), (4) 1%, 3%, or 10% porcine serum plus zymosan (1 mg/mL),
1%, 3%, or 10% human serum plus zymosan (1 mg/mL), (6) 10% porcine serum plus zymosan (1 mg/mL) plus sCR1 (10 nmol/L), (7) 10% human serum plus zymosan (1 mg/mL) plus sCR1 (1 nmol/L), (8) C8-depleted human serum (10%) plus zymosan (1 mg/mL), (9) C8-depleted human serum (10%) plus zymosan (1 mg/mL) plus C8 (6 mu g/mL), (10) zymosanactivated human serum (10%), or (11) human recombinant C5a (0.1 mu mol/L). After 30 minutes, each bath was then washed with normal KH buffer and contracted with U46619 (50 nmol/L), and a second dose-response curve to BK or substance P was generated.
Inhibition of Basal Release of Nitric Oxide
Additional LAD rings were exposed to human serum (10%) or human serum (10%) plus zymosan (1 mg/mL) for 30
minutes. These vessels then were washed and exposed to L-NAME (100 mu mol/L) to inhibit the basal release of nitric oxide in these vessels. [26] Immunohistochemistry Tissue samples were blocked with 1% goat serum for 20 minutes at room temperature, washed, and then incubated with anti-human C5b-9 monoclonal antibody in phosphate-buffered saline (PBS) containing 1% bovine serum albumin for 1 hour. After the slides were washed, they were incubated with the FITC-labeled goat anti-mouse secondary antibody for 30 minutes, washed with PBS several times, and covered with antifade solution (SlowFade, Molecular Probes Inc) and coverslips for confocal microscopic analysis.
Confocal Microscopic Analysis
The specimens were analyzed with the Leica confocal laser scanning microscope equipped with an argon ion laser with an output power of 2 to 50 mW, two photomultiplier tubes, and narrow band filters. The argon laser has two excitation wavelengths, 488 and 514 nm. The apertures were set at the minimum size for optimal signal. Smaller apertures (pinhole) allow a narrower optical cross section and less background. [32, 33] The images are en face optical sections through the vertical axis of the tissue. Each image of the series was taken at 1.0-micro meter intervals in the 512 times 512 pixel format. The tissue sections for immunohistochemistry were viewed with a times 100 (numerical aperture, 1.0) water immersion lens. Optical sections were taken through 3 to 10 layers, depending on the intensity of the stain. The images were analyzed, enhanced, and stored on an optical disc. Pseudocolor images were computergenerated with a twofold computer enhancement. All samples were collected, analyzed, and enhanced under the same conditions.
Statistical Analysis
The data are presented as mean plus minus SEM. .05. Analyses were performed using CRUNCH 4 (Crunch Software Corp) and SIGMASTAT (Jandel Scientific) for the IBM computer.
Results
A total of 38 pigs were used in the present study. High K plus (100 mmol/L) KH buffer contracted the LAD rings by 10.5 plus minus 0.6 g. The first U46619-induced contraction was 73 plus minus 4% of the 100 mmol/L K plus KH buffer response.
Time Control Experiments
Zymosan, porcine (10%), or human (10%) serum did not significantly (P more than .05) alter U46619-induced contraction of the LAD rings compared with the first U46619 contraction ( 
Effect of Zymosan-Activated Porcine Serum on LAD Ring Contraction and Relaxation
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Zymosan-activated porcine serum attenuated BK-induced relaxation of the LAD rings Effect of Zymosan-Activated Human Serum on Substance P-Induced Relaxation LAD rings incubated with 10% human serum did not attenuate the EC 50 for substance P-induced relaxation ( Figure   4 , top). The EC 50 for substance P-induced relaxation of the LAD rings was 0.3 plus minus 0.1 and 0.5 plus minus 0.1 nmol/L (n equals 7, P equals NS) after incubation of the LAD rings in KH buffer (ie, control) and human serum (10%),
respectively. Substance P-induced relaxation was significantly attenuated when the LAD rings were incubated with
Ovid Effect of Zymosan-Induced Activation of Human Serum on Basal Release of Nitric Oxide ( Figure 5A ) shows a representative tracing of a porcine LAD ring receiving L-NAME (100 mu mol/L) after exposure to 10% human serum for 30 minutes. Exposure of six LAD rings to L-NAME after incubation in 10% human serum increased baseline tension by 8 plus minus 2%.
Ovid HS and from nine rings exposed to HS and zymosan (1 mg/mL). *P less than .05 vs HS.
( Figure 5B ) shows a representative tracing of a porcine LAD ring receiving L-NAME (100 mu mol/L) after exposure to 10% human serum and zymosan for 30 minutes. Exposure of nine LAD rings to L-NAME after incubation in 10% human serum and zymosan increased baseline tension by 2 plus minus 1%. We observed a significantly greater increase in tension above baseline after application of L-NAME to LAD rings exposed to 10% human serum compared with 10% human serum plus zymosan Figure 5C .
Role of Complement in Loss of Endothelium-Dependent Relaxation
Incubation of four LAD rings with 10% heat-inactivated (56 degrees C for 30 minutes) human serum plus zymosan (1 mg/mL) for 30 minutes did not attenuate the EC 50 for BK-induced relaxation compared with the control value (33 plus minus 7 versus 39 plus minus 19 nmol/L, respectively; P equals NS).
Administration of sCR1 (1 nmol/L) to zymosan-activated human serum (10%) did not significantly alter U46619-induced contraction of the LAD rings (n equals 6) compared with the first U46619-induced contraction (7.0 plus minus 1.9 versus 10.0 plus minus 2.6 g, respectively; P equals NS). Similarly, sCR1 (10 nmol/L) in the presence of zymosanactivated porcine serum (10%) did not significantly alter U46619-induced contraction of the LAD rings (n equals 6) compared with the first U46619-induced contraction (4.8 plus minus 0.5 versus 5.9 plus minus 0.4 g, respectively; P equals NS). sCR1 preserved BK-induced relaxation of the LAD rings incubated with zymosan-activated human serum Figure 6A or zymosan-activated porcine serum Figure 6B . The EC 50 of BK-induced relaxation of LAD rings in the KH buffer (ie, control) was 4 plus minus 1 and 2 plus minus 1 nmol/L before and after sCR1 treatment of zymosan-activated human serum ( Figure 6A , P equals NS). Similarly, 10 nmol/L sCR1 preserved BK-induced relaxation of LAD rings (n equals 6) incubated with zymosan-activated porcine serum. The EC 50 for BK-induced relaxation was 9 plus minus 4 and 10 plus minus 3 nmol/L (P equals NS) before and after sCR1 treatment of zymosan-activated porcine serum, respectively.
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Role of C8 in the Loss of Endothelium-Dependent Relaxation
Zymosan-activated C8-depleted human serum (10%) did not significantly alter U46619-induced contraction of the LAD rings (n equals 7) compared with the first U46619-induced contraction (5.8 plus minus 0.7 versus 4.1 plus minus 0.9 g, respectively; P equals NS). Similarly, addition of C8 (6 mu g/mL) to zymosan-activated C8-depleted human serum (10%) did not significantly alter U46619-induced contraction of the LAD rings (n equals 12) compared with the first U46619-induced contraction (3.1 plus minus 0.7 versus 5.1 plus minus 0.8 g, respectively; P equals NS).
LAD rings incubated with zymosan-activated C8-depleted human serum demonstrated no significant loss of BK-induced relaxation Figure 7A . The EC 50 for BK-induced relaxation of the LAD rings was 3 plus minus 1 nmol/L before and after incubation of the LAD rings with zymosan-activated C8-depleted human serum. In contrast, addition of C8 (6 mu g/mL) to zymosan-activated C8-depleted human serum significantly attenuated endothelium-dependent relaxation Ovid: Complement-Mediated Loss of Endothelium-Dependent Relaxation ... http://ovidsp.tx.ovid.com.ezp-prod1.hul.harvard.edu/sp-3.5.1a/ovidweb.cgi 9 of 18 2/17/2012 11:01 AM Figure 7B . The EC 50 for BK-induced relaxation of the LAD rings in KH buffer was 4 plus minus 1 nmol/L and increased significantly (P less than .05) to 423 plus minus 141 nmol/L after the addition of C8 (6 mu g/mL) to zymosan-activated C8-depleted human serum. The EC 50 for BK-induced relaxation of LAD rings after incubation with 10% C8-depleted serum plus C8 plus zymosan was not significantly different from that found with 10% human serum plus zymosan (423 plus minus 141 versus 418 plus minus 159 nmol/L, respectively). Scale bar represents computer-generated scale of fluorescent staining intensity. The scale ranges from black/rust (low-intensity staining) through orange/yellow (moderate staining) to white/blue (high-intensity staining). The high autofluorescence of the elastic lamina is apparent in all figures. Original magnification times 250 for all panels.
Discussion
Several important findings were observed in the present study. Activation of 10% human or porcine serum with zymosan attenuated endothelium-dependent relaxation of porcine LAD rings. Basal release of nitric oxide was significantly inhibited by exposure of LAD rings to zymosan-activated human serum. sCR1 prevented zymosan-activated porcine serum-or human serum-induced loss of endothelium-dependent relaxation. Addition of recombinant human C5a or previously generated complement products (ie, zymosan-activated human serum) failed to attenuate endothelium-dependent relaxation. Removal of the complement component C8 in human serum also prevented the loss of endothelium-dependent relaxation induced by zymosan-activated human serum. The addition of C8 to C8-depleted human serum followed by zymosan activation significantly attenuated endothelium-dependent relaxation.
Immunohistochemical staining of the coronary vessels demonstrated the presence of immunoreactive C5b-9 on the luminal surface of the vascular endothelium. Thus, we have demonstrated that complement activation directly attenuates endothelium-dependent relaxation of the porcine coronary vasculature, with the concomitant presence of C5b-9 on the endothelial cell membrane. These results suggest that the terminal MAC (ie, C5b-9) initiates the loss of endothelium-dependent relaxation in this model.
Role of Complement in the Loss of Endothelium-Dependent Relaxation of Coronary Vessels
Ovid: Complement-Mediated Loss of Endothelium-Dependent Relaxation ... http://ovidsp.tx.ovid.com.ezp-prod1.hul.harvard.edu/sp-3.5.1a/ovidweb.cgi 11 of 18 2/17/2012 11:01 AM
The role of complement in the loss of endothelium-dependent relaxation of the coronary vasculature has not been studied. Complement activation may attenuate endothelium-dependent relaxation directly or indirectly.
Complement activation results in the production of C5a, a potent chemotaxin and PMN-aggregating and -activating anaphylatoxin. [36, 37] Thus, C5a production following reperfusion could attenuate endothelium-dependent relaxation of coronary vessels indirectly by activating PMNs. Additionally, C5a has been shown to release heparan sulfate from porcine endothelial cells. Heparan sulfate tethers superoxide dismutase to the endothelial cell and secures the endothelial cell to the extracellular matrix. [23, 24] In the present study, the addition of a high concentration of human C5a (0.1 mu mol/L) did not attenuate BK-induced relaxation of the porcine LAD rings. Additionally, the addition of zymosan-activated human serum, which contains C3a/C3a des-Arg, C5a/C5a des-Arg, and soluble C5b-9, did not attenuate endothelium-dependent relaxation. These data are similar to a preliminary study by Rendig et al, [38] which demonstrated that C5a does not attenuate endothelium-dependent relaxation of the porcine microvasculature.
Further, zymosan-activated C8-depleted human serum did not attenuate BK-induced relaxation in the present study.
One would expect C5a and C3a to be produced after zymosan activation of C8-depleted human serum, although C5a
and C3a were not measured in these experiments. Thus, it appears that the anaphylatoxins, C5a and C3a, do not directly attenuate endothelium-dependent relaxation of porcine coronary arteries in this model.
The formation of membrane-bound C5b-9 could directly attenuate endothelium-dependent relaxation of the porcine coronary artery rings. It is well known that C5b-9 forms transmembrane pores; in nonnucleated cells, this activity results in cellular lysis. It is less appreciated that the formation of C5b-9 may directly cause cellular activation in the absence of cellular lysis. Lysis of nucleated cells is less likely because of the presence of various membrane-bound complement regulatory proteins or homologous restriction factors, including CD59 (protectin), CD46
(membrane cofactor protein, MCP), CD55 (decay-accelerating factor), and C8 binding protein. [39] [40] [41] [42] Endothelial cells have two well-characterized membrane-bound proteins, CD59 and CD55, that restrict complement activation at the plasma membrane. [43] The regulation of C5b-9 formation by CD59 and CD55 is generally considered to be species restricted. However, recent observations by Van den Berg and Morgan [44] suggest that porcine CD59 may not be homologously restricted. We observed concentration-dependent inhibition of endothelium-dependent relaxation after activation of 3% to 10% human serum. However, we observed a significant loss of endothelium-dependent relaxation of porcine coronary arteries only after activation of 7% to 10% porcine serum. These data suggest that porcine endothelial cell complement-regulatory mechanisms do not efficiently recognize human complement but effectively attenuate low levels of porcine complement activation.
It is unlikely that zymosan-activated serum resulted in the direct lysis of porcine endothelial cells in the present study for several reasons. First, in a series of histochemical studies attempting to demonstrate the presence of C5b-9
on endothelial cells, we observed no damage to the microscopic appearance of the endothelial cells, except when extremely high concentrations of activated complement (100% activated serum) were used. Second, the membrane regulators of complement activation (ie, CD59 and CD55) would have been able to effectively inhibit lytic concentrations of C5b-9 in only 10% serum. Third, endothelial cells exposed to other species of complement are not easily lysed even after 48 hours of exposure to complement. [45] Fourth, one would expect to observe a significant attenuation or augmentation of the contractile effect of U46619 in the present study, a finding that was not observed.
Therefore, we postulate that it is more likely that C5b-9 formed sublytic concentrations of transmembrane pores in the present study. We speculate that C5b-9 leads to the activation of the endothelium and the loss of endotheliumdependent relaxation. However, this assumption is speculative and warrants further investigation.
Endothelium-Dependent Relaxation and Nitric Oxide Formation
It is well known that porcine coronary arteries and endothelial cells release multiple EDRFs when exposed to BK. [30, 31] Thus, the loss of BK-induced porcine coronary artery relaxation resulted from a loss of endothelium-`d ependent'' relaxation in the present study. However, substance P releases only nitric oxide from porcine endothelial cells. [29] Thus, we conclude that the attenuated substance P-induced relaxation of LAD rings, exposed to zymosan-activated human serum, was a result of altered nitric oxide-induced relaxation.
Vascular ring preparations, like those performed in the present study, release basal amounts of nitric oxide from normal functioning endothelial cells. [26] We observed that the addition of L-NAME to LAD rings exposed to human serum resulted in contraction of the vascular smooth muscle. Further, LAD rings exposed to 10% human serum relaxed in the presence of BK or substance P. These data demonstrate that both basal nitric oxide and mediator-induced release of nitric oxide are not inhibited by 10% human serum in this model. In contrast, LAD rings exposed to human serum and zymosan contracted significantly less to L-NAME and relaxed significantly less to substance P or BK. Thus, complement attenuates not only the pharmacologically induced release of nitric oxide but the basal release as well.
Future studies will investigate the mechanism(s) by which C5b-9 attenuates nitric oxide-induced relaxation.
Possible Role of C5b-9 in Myocardial Ischemia and Reperfusion
There is reason to suspect that the terminal MAC (C5b-9) is an important mediator of ischemia and reperfusion injury. First, C5b-9 directly induces myocardial dysfunction in the isolated perfused rabbit heart. [18, 19, 46] presence of C5b-9 on endothelial cells is unknown.
In the present study, we demonstrate that either zymosan-activated porcine or human serum results in a loss of endothelium-dependent relaxation of porcine coronary arteries and is associated with deposition of C5b-9 on the endothelial cells. Further, we have shown that the basal release of nitric oxide was also attenuated by zymosanactivated serum. The loss of endothelium-dependent relaxation appears to be mediated by the formation of C5b-9, since depletion and subsequent addition of C8 resulted in normal and abnormal endothelium-dependent relaxation of the LAD rings, respectively. The loss of a functional endothelial cell lining in the myocardium could be potentially harmful to an already ischemic vascular bed. Loss of endothelium-dependent relaxation may predispose the coronary vasculature to vasoconstrictive metabolites formed during ischemia and reperfusion and lead to vasospasm. Along these lines, complement activation has been shown to play a significant role in cerebral vasospasm following subarachnoid hemorrhage in humans.
[50] These data suggest that complement activation during myocardial ischemia and reperfusion may result in the loss or attenuation of endothelium-dependent relaxation.
Complement activation and C5b-9 formation have been shown to upregulate P-selectin on endothelial cells. [25, 26] Recent data suggest that inhibition of nitric oxide synthase with L-NAME induces the upregulation of P-selectin.
[51] P-selectin is necessary for PMN-endothelial cell adherence and the resulting transendothelial migration. [9] Furthermore, inhibition of P-selectin function protects the feline myocardium from ischemia and reperfusion injury. [9, 52] Thus, complement activation may be an early and possibly a necessary factor in the upregulation of P-selectin and transcellular migration of PMNs after ischemia and reperfusion.
Limitations of the Present Model
We have shown recently that complement activation is observed immediately on reperfusion of the ischemic porcine myocardium. [13] However, the present LAD ring preparation is not a model of ischemia and reperfusion.
Whether complement-mediated loss of endothelium-dependent relaxation takes place in vivo remains unknown.
Further, regulation of coronary blood flow is at the arteriolar level. It is unknown at present whether complement attenuates endothelium-dependent relaxation of the microvasculature. Future studies in our laboratory will examine the effects of complement activation on the microvasculature in vitro and after ischemia and reperfusion in vivo.
Summary and Conclusion
We have shown that activation of the complement cascade directly attenuates the endothelium-dependent relaxation of porcine coronary arteries. The formation of C5b-9 is the contributing factor in the loss of endotheliumdependent relaxation after complement activation. These studies demonstrate that in addition to oxygenderived free radicals and activated PMNs, complement can directly attenuate the endothelium-dependent relaxation of coronary arteries and possibly lead to coronary vasospasm.
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